Fresh analysis reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who halt conventional lifestyle regimens.
Published data in a major medical journal shows that while overweight people often shed about a fifth of their total mass while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users using such drugs should be informed of the risk of rapid rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a reversion to starting mass in about a year and a half.
Comparing Approaches
The analysis, which reviewed 37 of studies involving thousands of patients, compared the effects of these new drugs with other pills.
The team point out that people who lose weight through diet and exercise usually see a less rapid creep back—around 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Experts believe the mechanism of the jabs is key to understanding the accelerated weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' results in appetite is unsuppressed, making binge eating a significant risk."
A Chronic Issue?
Health authorities advise the injections for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, considering the high risk of weight regain, the therapy might need to be long-term.
This opinion is echoed by drug manufacturers, who say that the findings "highlight the chronic character of excess weight," akin to managing diseases like high blood pressure.
User Testimonies
Individuals who have stopped the jabs explain a powerful resurgence of cravings.
"It was like a trigger activating and you're instantly ravenous," described an individual.
This challenge is compounded if patients have not developed lasting lifestyle or habit modifications during therapy.
Growing Interest
Recent estimates show that millions of people in the UK have used these injections in the past year, with interest continuing to grow.
- Use is higher among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while the jabs are potent tools for weight loss, they are not a permanent solution and lasting health benefits hinges on integrated behavioural support.
